Deep vein thrombosis propylaxis: better living through chemistry-affirms

Bryant Ho, Michael H. Huo

Research output: Contribution to journalArticle

Abstract

Increasing numbers of total joint replacement surgeries are being performed in the United States. One of the most frequent complications from these procedures is venous thromboembolism. Prophylaxis is accepted as the standard of care by all the stakeholders: physicians, patient advocacy groups, payers, and government agencies. Debate and disagreement persist with regard to the most clinically efficacious and safe prophylaxis regimen. There are differences between the guideline recommendations from different organizations: American College of Chest Physicians and American Academy of Orthopaedic Surgeons. This review focuses on summarizing some of the differences in the recommended chemoprophylaxis for orthopedic patients undergoing total joint replacement surgery. We have also included a discussion of newer agents in clinical development.

Original languageEnglish (US)
Pages (from-to)80-84
Number of pages5
JournalSeminars in Arthroplasty
Volume21
Issue number2
DOIs
StatePublished - Jun 2010

Fingerprint

Replacement Arthroplasties
Venous Thrombosis
Patient Advocacy
Government Agencies
Venous Thromboembolism
Chemoprevention
Standard of Care
Orthopedics
Organizations
Guidelines
Physicians

Keywords

  • Chemoprophylaxis
  • Prophylaxis
  • Total hip replacement
  • Total knee replacement
  • Venous thromboembolism

ASJC Scopus subject areas

  • Orthopedics and Sports Medicine
  • Surgery

Cite this

Deep vein thrombosis propylaxis : better living through chemistry-affirms. / Ho, Bryant; Huo, Michael H.

In: Seminars in Arthroplasty, Vol. 21, No. 2, 06.2010, p. 80-84.

Research output: Contribution to journalArticle

@article{f731734d3442491ab14b65ed3751b234,
title = "Deep vein thrombosis propylaxis: better living through chemistry-affirms",
abstract = "Increasing numbers of total joint replacement surgeries are being performed in the United States. One of the most frequent complications from these procedures is venous thromboembolism. Prophylaxis is accepted as the standard of care by all the stakeholders: physicians, patient advocacy groups, payers, and government agencies. Debate and disagreement persist with regard to the most clinically efficacious and safe prophylaxis regimen. There are differences between the guideline recommendations from different organizations: American College of Chest Physicians and American Academy of Orthopaedic Surgeons. This review focuses on summarizing some of the differences in the recommended chemoprophylaxis for orthopedic patients undergoing total joint replacement surgery. We have also included a discussion of newer agents in clinical development.",
keywords = "Chemoprophylaxis, Prophylaxis, Total hip replacement, Total knee replacement, Venous thromboembolism",
author = "Bryant Ho and Huo, {Michael H.}",
year = "2010",
month = "6",
doi = "10.1053/j.sart.2009.12.011",
language = "English (US)",
volume = "21",
pages = "80--84",
journal = "Seminars in Arthroplasty",
issn = "1045-4527",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - Deep vein thrombosis propylaxis

T2 - better living through chemistry-affirms

AU - Ho, Bryant

AU - Huo, Michael H.

PY - 2010/6

Y1 - 2010/6

N2 - Increasing numbers of total joint replacement surgeries are being performed in the United States. One of the most frequent complications from these procedures is venous thromboembolism. Prophylaxis is accepted as the standard of care by all the stakeholders: physicians, patient advocacy groups, payers, and government agencies. Debate and disagreement persist with regard to the most clinically efficacious and safe prophylaxis regimen. There are differences between the guideline recommendations from different organizations: American College of Chest Physicians and American Academy of Orthopaedic Surgeons. This review focuses on summarizing some of the differences in the recommended chemoprophylaxis for orthopedic patients undergoing total joint replacement surgery. We have also included a discussion of newer agents in clinical development.

AB - Increasing numbers of total joint replacement surgeries are being performed in the United States. One of the most frequent complications from these procedures is venous thromboembolism. Prophylaxis is accepted as the standard of care by all the stakeholders: physicians, patient advocacy groups, payers, and government agencies. Debate and disagreement persist with regard to the most clinically efficacious and safe prophylaxis regimen. There are differences between the guideline recommendations from different organizations: American College of Chest Physicians and American Academy of Orthopaedic Surgeons. This review focuses on summarizing some of the differences in the recommended chemoprophylaxis for orthopedic patients undergoing total joint replacement surgery. We have also included a discussion of newer agents in clinical development.

KW - Chemoprophylaxis

KW - Prophylaxis

KW - Total hip replacement

KW - Total knee replacement

KW - Venous thromboembolism

UR - http://www.scopus.com/inward/record.url?scp=77953893808&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953893808&partnerID=8YFLogxK

U2 - 10.1053/j.sart.2009.12.011

DO - 10.1053/j.sart.2009.12.011

M3 - Article

AN - SCOPUS:77953893808

VL - 21

SP - 80

EP - 84

JO - Seminars in Arthroplasty

JF - Seminars in Arthroplasty

SN - 1045-4527

IS - 2

ER -